Oridonin Delays Aging Through the AKT Signaling Pathway
Authors:
Open Access
- 18 May 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 888247
Abstract
Aging is a major risk factor for chronic diseases and disability in humans. Nowadays, no effective anti-aging treatment is available clinically. In this study, oridonin was selected based on the drug screening strategy similar to Connectivity MAP (CMAP) but upon transcriptomes of 102 traditional Chinese medicines treated cell lines. Oridonin is a diterpenoid isolated from Rabdosia rubescens. As reported, Oridonin exhibits a variety of pharmacological activities, including antitumor, antibacterial and anti-inflammatory activities. Here, we found that oridonin inhibited cellular senescence in human diploid fibroblasts (2BS and WI-38), manifested by decreased senescence-associated β-galactosidase (SA-β-gal) staining. Compared with the elderly control group, the positive cell rate in the oridonin intervention group was reduced to 48.5%. Notably, oridonin prolonged the lifespan of yeast by 48.9%, and extended the average life span of naturally aged mice by 21.6%. Our mice behavior experiments exhibited that oridonin significantly improved the health status of naturally aged mice. In addition, oridonin also delayed doxorubicin-induced cellular senescence and mouse senescence. Compared with the model group, the percentage of SA-β-gal positive cells in the oridonin treatment group was reduced to 59.8%. It extended the average lifespan of mice by 53.8% and improved healthspan. Mechanistically, we showed that oridonin delayed aging through the AKT signaling pathway and reversed the genetic changes caused by doxorubicin-induced cell senescence. Therefore, oridonin is a potential candidate for the development of anti-aging drugs.Keywords
This publication has 53 references indexed in Scilit:
- Molecular phenotyping of aging in single yeast cells using a novel microfluidic deviceAging Cell, 2012
- Interplay between FOXO, TOR, and AktBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Clinical presentation and management of mTOR inhibitor-associated stomatitisOral Oncology, 2011
- Therapy-Induced Senescence in CancerJNCI: Journal of the National Cancer Institute, 2010
- Rapamycin fed late in life extends lifespan in genetically heterogeneous miceNature, 2009
- Use of Sirolimus in Solid Organ TransplantationDrugs, 2007
- Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivoBlood, 2006
- The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and DiseaseScience, 2006
- CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct MechanismsMolecular and Cellular Biology, 2005
- Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell ProliferationCell, 2004